- Home
- PTGX vs TFX Comparison
PTGX vs TFX Comparison
Compare PTGX & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | TFX |
|---|---|---|
| Founded | 2006 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.6B |
| IPO Year | 2016 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PTGX | TFX |
|---|---|---|
| Price | $105.55 | $132.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | $108.23 | ★ $138.75 |
| AVG Volume (30 Days) | 713.3K | ★ 754.4K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,992,713,000.00 |
| Revenue This Year | $873.97 | $15.97 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.29 | $100.18 |
| 52 Week High | $107.84 | $138.93 |
Technical Indicators
Market Signals| Indicator | PTGX | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 75.05 |
| Support Level | $76.63 | $102.20 |
| Resistance Level | $107.84 | $136.46 |
| Average True Range (ATR) | 4.03 | 3.82 |
| MACD | -0.12 | 1.59 |
| Stochastic Oscillator | 84.57 | 87.07 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.